Payment overview · 2025
General Payments
$140.81
4 reported records · 3 companies
Healthcare provider profile · identity verified
Arlin Monroe Myrmoe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ABERDEEN, SD · NPI 1184893349
Verified facts
What the public records show
CMS Open Payments records show Arlin Monroe Myrmoe, M.D. received $140.81 in general payments during 2025 across 4 reported records.
Phathom Pharmaceuticals, Inc. accounted for 62.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.34 | 62.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.39 | 27.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.81 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $88.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1510 | 306 |
| Amlodipine Besylate | Amlodipine Besylate | 1275 | 249 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1134 | 218 |
| Losartan Potassium | Losartan Potassium | 924 | 197 |
| Omeprazole | Omeprazole | 852 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 812 | 195 |
| Metoprolol Succinate | Metoprolol Succinate | 748 | 156 |
| Potassium Chloride | Potassium Chloride | 722 | 137 |
| Furosemide | Furosemide | 699 | 138 |
| Eliquis | Apixaban | 632 | 97 |
| Lisinopril | Lisinopril | 516 | 111 |
| Metformin Hcl | Metformin Hcl | 491 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 477 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 434 | 90 |
| Sertraline Hcl | Sertraline Hcl | 429 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 362 | 74 |
| Gabapentin | Gabapentin | 358 | 54 |
| Warfarin Sodium | Warfarin Sodium | 323 | 40 |
| Allopurinol | Allopurinol | 290 | 57 |
| Simvastatin | Simvastatin | 262 | 57 |
| Finasteride | Finasteride | 236 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 43 |
| Jardiance | Empagliflozin | 209 | 32 |
| Ezetimibe | Ezetimibe | 206 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 44 |
| Atenolol | Atenolol | 191 | 35 |
| Alendronate Sodium | Alendronate Sodium | 188 | 37 |
| Carvedilol | Carvedilol | 186 | 41 |
| Ozempic | Semaglutide | 178 | 30 |
| Metformin Hcl Er | Metformin Hcl | 177 | 43 |
| Famotidine | Famotidine | 166 | 30 |
| Montelukast Sodium | Montelukast Sodium | 120 | 21 |
| Trazodone Hcl | Trazodone Hcl | 117 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 22 |
| Donepezil Hcl | Donepezil Hcl | 111 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 108 | 20 |
| Spironolactone | Spironolactone | 106 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 28 |
| Xarelto | Rivaroxaban | 98 | 19 |
| Prednisone | Prednisone | 93 | 25 |
| Fenofibrate | Fenofibrate | 89 | 15 |
| Irbesartan | Irbesartan | 89 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 14 |
| Propranolol Hcl | Propranolol Hcl | 83 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 26 |
| Glimepiride | Glimepiride | 79 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | 11 |
| Memantine Hcl | Memantine Hcl | 68 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 16 |
| Chlorthalidone | Chlorthalidone | 61 | 18 |
| Novolog Flexpen | Insulin Aspart | 58 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 53 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Valsartan | Valsartan | 53 | 11 |
| Glipizide | Glipizide | 52 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | suppressed |
| Jantoven | Warfarin Sodium | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 46 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Lactulose | Lactulose | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 11 |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Calcitriol | Calcitriol | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | 18 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Meloxicam | Meloxicam | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | 14 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Methimazole | Methimazole | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 27 | 27 |
| Niacin Er | Niacin | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Desmopressin Acetate | Desmopressin Acetate | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Azithromycin | Azithromycin | 13 | 12 |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.81 · 4 records | Phathom Pharmaceuticals, Inc. | GVOKE HYPOPEN, JARDIANCE, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error